298 related articles for article (PubMed ID: 21248754)
21. Eplerenone Prevents Atrial Fibrosis via the TGF-β Signaling Pathway.
Du L; Qin M; Yi Y; Chen X; Jiang W; Zhou L; Zhang D; Xu K; Yang Y; Li C; Liu Y; Liu X; Duan SZ
Cardiology; 2017; 138(1):55-62. PubMed ID: 28571007
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice.
Pojoga LH; Adamová Z; Kumar A; Stennett AK; Romero JR; Adler GK; Williams GH; Khalil RA
Am J Physiol Heart Circ Physiol; 2010 Jun; 298(6):H1776-88. PubMed ID: 20363891
[TBL] [Abstract][Full Text] [Related]
23. Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Urabe A; Izumi T; Abe Y; Taniguchi I; Mochizuki S
Hypertens Res; 2006 Aug; 29(8):627-34. PubMed ID: 17137219
[TBL] [Abstract][Full Text] [Related]
24. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway.
Saka M; Obata K; Ichihara S; Cheng XW; Kimata H; Noda A; Izawa H; Nagata K; Yokota M
Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1164-71. PubMed ID: 17184496
[TBL] [Abstract][Full Text] [Related]
25. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions.
Wang H; Shimosawa T; Matsui H; Kaneko T; Ogura S; Uetake Y; Takenaka K; Yatomi Y; Fujita T
J Hypertens; 2008 Jul; 26(7):1453-62. PubMed ID: 18551023
[TBL] [Abstract][Full Text] [Related]
26. Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
Yasuoka S; Kai H; Kajimoto H; Kudo H; Takayama N; Anegawa T; Koga M; Miyamoto T; Mifune H; Kage M; Hirooka Y; Imaizumi T
Circ J; 2013; 77(6):1474-81. PubMed ID: 23470864
[TBL] [Abstract][Full Text] [Related]
27. Role of Rac1 GTPase in salt-sensitive hypertension.
Nagase M
Curr Opin Nephrol Hypertens; 2013 Mar; 22(2):148-55. PubMed ID: 23377658
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation.
Tsai CT; Chiang FT; Tseng CD; Hwang JJ; Kuo KT; Wu CK; Yu CC; Wang YC; Lai LP; Lin JL
J Am Coll Cardiol; 2010 Feb; 55(8):758-70. PubMed ID: 20170814
[TBL] [Abstract][Full Text] [Related]
29. Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats.
Xu D; Murakoshi N; Tajiri K; Duo F; Okabe Y; Murakata Y; Yuan Z; Li S; Aonuma K; Song Z; Shimoda Y; Mori H; Sato A; Nogami A; Aonuma K; Ieda M
Clin Sci (Lond); 2021 Oct; 135(20):2409-2422. PubMed ID: 34386810
[TBL] [Abstract][Full Text] [Related]
30. Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits.
Liu T; Zhao H; Li J; Korantzopoulos P; Li G
Cardiovasc Ther; 2014 Aug; 32(4):178-83. PubMed ID: 24814361
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition.
Okazaki H; Minamino T; Tsukamoto O; Kim J; Okada K; Myoishi M; Wakeno M; Takashima S; Mochizuki N; Kitakaze M
Hypertens Res; 2006 Apr; 29(4):277-84. PubMed ID: 16778335
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.
Biala A; Finckenberg P; Korpi A; Loytainen M; Martonen E; Levijoki J; Mervaala E
J Physiol Pharmacol; 2011 Jun; 62(3):275-85. PubMed ID: 21893687
[TBL] [Abstract][Full Text] [Related]
33. High Salt Intake-Increased (Pro)renin Receptor Expression Is Exaggerated in the Kidney of Dahl Salt-Sensitive Rats.
Yamakoshi S; Ito O; Rong R; Ohsaki Y; Nakamura T; Hirose T; Takahashi K; Mori T; Totsune K; Kohzuki M
Hypertension; 2020 Jun; 75(6):1447-1454. PubMed ID: 32336231
[TBL] [Abstract][Full Text] [Related]
34. Aberrant Rac1-mineralocorticoid receptor pathways in salt-sensitive hypertension.
Kawarazaki W; Fujita T
Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):929-36. PubMed ID: 24111570
[TBL] [Abstract][Full Text] [Related]
35. Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload-Induced Cardiac Injury.
Ayuzawa N; Nagase M; Ueda K; Nishimoto M; Kawarazaki W; Marumo T; Aiba A; Sakurai T; Shindo T; Fujita T
Hypertension; 2016 Jan; 67(1):99-106. PubMed ID: 26527051
[TBL] [Abstract][Full Text] [Related]
36. Mediators of mineralocorticoid receptor-induced profibrotic inflammatory responses in the heart.
Wilson P; Morgan J; Funder JW; Fuller PJ; Young MJ
Clin Sci (Lond); 2009 May; 116(9):731-9. PubMed ID: 18990085
[TBL] [Abstract][Full Text] [Related]
37. Eplerenone inhibits atrial fibrosis in mutant TGF-β1 transgenic mice.
Chen X; Zhang W; Wang Q; Du L; Yi Y; Liu Y; Liu X; Duan S
Sci China Life Sci; 2016 Oct; 59(10):1042-1047. PubMed ID: 27333789
[TBL] [Abstract][Full Text] [Related]
38. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
Nagase M; Shibata S; Yoshida S; Nagase T; Gotoda T; Fujita T
Hypertension; 2006 Jun; 47(6):1084-93. PubMed ID: 16636193
[TBL] [Abstract][Full Text] [Related]
39. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing.
Zhao J; Li J; Li W; Li Y; Shan H; Gong Y; Yang B
Br J Pharmacol; 2010 Apr; 159(8):1584-94. PubMed ID: 20082611
[TBL] [Abstract][Full Text] [Related]
40. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
Bayorh MA; Mann G; Walton M; Eatman D
Clin Exp Hypertens; 2006 Feb; 28(2):121-32. PubMed ID: 16546838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
